Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor … – BioSpace,

Published: Jan 13, 2022. Previous clinical trials demonstrated ASC40 is safe and inhibits human facial sebum production in a dose-dependent …, Published: Jan 13, 2022. Previous clinical trials demonstrated ASC40 is safe and inhibits human facial sebum production in a dose-dependent …, Read More

Scroll to Top